Erasca, Inc. Prices Upsized $225 Million Public Offering
ERAS has more than doubled off its 52-week low of $1.01 on elevated volume (2.7× avg).
Summary
Erasca, Inc. has priced its upsized public offering of 22.5 million shares at $10.00 per share, raising $225 million. The proceeds will be used to fund research and development and for general corporate purposes.
Key Events · Financing and Capital Events · ERAS
-
Offering Priced at $10.00/Share
Erasca, Inc. priced its public offering of 22.5 million shares at $10.00 per share, consistent with the market price before the offering.
-
Gross Proceeds of $225 Million
The offering is expected to generate gross proceeds of $225 million before deducting underwriting discounts and commissions.
-
Use of Proceeds
Erasca intends to use the net proceeds to fund research and development of its product candidates and for working capital and other general corporate purposes.
Analysis · ERAS · Life Sciences
Erasca, Inc. has finalized the terms for its public offering, initially announced on January 20, 2026. The offering priced at $10.00 per share, aligning with the market price at the time of announcement. This capital raise strengthens Erasca's balance sheet, providing resources for ongoing clinical trials and research programs. Investors should monitor the progress of Erasca's RAS/MAPK pipeline and upcoming data releases.
At the time of this filing, ERAS was trading at $10.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $1.01 to $10.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.